Cumberland Pharmaceuticals Says Ifetroban Is Well Tolerated in Phase 2a Systemic Sclerosis Trial
Bitget2026/10/23 20:05- Cumberland Pharmaceuticals announced Phase 2a ASSIST-SSc top-line results on Oct. 23, 2026, showing oral ifetroban was generally well tolerated in systemic sclerosis patients.
- Gastrointestinal and bleeding-related adverse events were more frequent with ifetroban but predominantly mild; no serious adverse events were attributed to treatment.
- The trial was not designed to establish efficacy; limited disease progression and its small size prevented conclusions about treatment benefits.
- Planned biomarker studies and cardiac imaging evaluations will inform decisions on further development in systemic sclerosis.
- The company plans to submit the clinical study report to the U.S. Food and Drug Administration.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Apple plans to raise 7 billions USD to repurchase stocks, returning to the US dollar bond market after a year and a half.
Apple raised approximately $7 billion through this bond issuance, which is divided into seven tranches with maturities ranging from two to ten years. The longest tranche was initially priced at a spread of 80 basis points over US Treasuries. The proceeds from the bonds will be used for general corporate purposes, including stock buybacks, dividend payments, and capital expenditures. Analysts pointed out that shareholder returns are a higher priority than AI capital expenditures in Apple's capital allocation.
BUZZ - Sun Life Financial shares fall after Q3 earnings release
Pegasystems Wins 10-Year U.S. Army Contract Worth Up to $419 Million
Crypto prices
More
